Item 1.01. Entry into a Material Definitive Agreement.

BioScrip, Inc. (the "Company") entered into a Prime Vendor Agreement ("Agreement") with AmerisourceBergen Drug Corporation ("ABDC") effective August 25, 2009, under which the Company will purchase from ABDC substantially all of its prescription products, subject to certain minimum periodic purchase levels and excluding purchases of therapeutic plasma products. Under the Agreement, ABDC will also provide related services to the Company.

The Agreement is for a term of three (3) years and may be extended for up to two
(2) additional years upon mutual written agreement of ABDC and the Company. Under certain circumstances, if the Agreement is terminated prior to the end of the term, the Company would be required to pay ABDC an early termination penalty.

Additionally, the Agreement requires the Company to participate in ABDC's PRxO Generics™ Program and purchase from ABDC a specified percentage of its requirements for generic pharmaceuticals.

Pricing of pharmaceutical products under the Agreement is generally based on published wholesale acquisition costs, less certain discounts, rebates and other adjustments that vary with the type of products being purchased.

The Agreement also provides for the supply by ABDC of some over-the-counter medications, nutritional, health and beauty care products, and home health care products.

Item 1.02. Termination of a Material Definitive Agreement.

On August 25, 2009 the Company's Prime Vendor Agreement with Cardinal Health 110, Inc. terminated.

---